论文部分内容阅读
一、引言萘啶酸在临床上应用已20余年,其抗菌谱仅为大多数肠杆菌科细菌,假单胞菌和革蓝氏阳性菌则对其耐药.考虑到低血浓度、耐药突变和耐受性影响,而活性和非活性代谢物存在于尿中,故萘啶酸仅用于治疗尿道感染.对萘啶酸的结构改造,引出了第二代喹诺酮药物:奥索利酸、吡哌酸、西诺沙星、acrosoxacin和氟甲喹.这些药物除体外对革蓝氏阴性菌的活性高于萘啶酸外,对治疗临床感染仍无建树,同样被局限于尿道感染的治疗范围,有时也用于治疗假单胞菌引起
First, the introduction of nalidixic acid in clinical application has been more than 20 years, the antibacterial spectrum is only the majority of Enterobacteriaceae bacteria, Pseudomonas and GenBank is resistant to it. Taking into account the low blood concentration, resistance Mutation and tolerance, and active and inactive metabolites exist in the urine, nalidixic acid is only used to treat urinary tract infections.Narixinic acid structural transformation, leads to the second generation of quinolone drugs: Oxalic acid , Pipemidic acid, cinoxacin, acrosoxacin and flumequine, these drugs in addition to the activity of gram-negative bacteria in vitro than nalidixic acid, the treatment of clinical infection still no achievements, also limited to urinary tract infections Treatment range, sometimes used to treat Pseudomonas caused